SpringWorks Therapeutics, Inc. (SWTX)
Chart Events
Performance Outlook
| Previous Close | 39.66 |
| Open | 38.66 |
| Bid | 37.13 x 800 |
| Ask | 37.30 x 800 |
| Day's Range | 36.90 - 39.18 |
| 52 Week Range | 13.60 - 81.67 |
| Volume | |
| Avg. Volume | 1,316,212 |
| Market Cap | 1.824B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.21 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 76.25 |
- GlobeNewswire
SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
– Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key Secondary Endpoints – – Encouraging Preliminary Data from Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma Presented at ASCO; Combination Continues in Ongoing Phase 2 Trial and Expands into Additional Sub-Studies with Standard of Care Agents – – Mirdametinib Monotherapy and Comb
- GlobeNewswire
SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference
STAMFORD, Conn., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Wednesday, August 10th at 10:55 a.m. ET. To access the live webcast please visit the Events & Presentations page within the Investors & Media
- GlobeNewswire
SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors
STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company’s Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. (“AbbVie”) until his retirement last year, brings over 30 years of experience in global comme
